tbuckley/cabot-search huggingface dataset:
PhaseDancer: a novel targeted assembler of segmental duplications unravels the complexity of the human chromosome 2 fusion going from 48 to 46 chromosomes in hominin evolution
Authors: Barbara Poszewiecka, Krzysztof Gogolewski, Justyna A. Karolak, Paweł Stankiewicz, Anna Gambin
Journal: Genome biology (2023)

Abstract Resolving complex genomic regions rich in segmental duplications (SDs) is challenging due to the high error rate of long-read sequencing. Here, we describe a targeted approach with a novel genome assembler PhaseDancer that extends SD-rich regions of interest iteratively. We validate its robustness and efficiency using a golden-standard set of human BAC clones and in silico-generated SDs with predefined evolutionary scenarios. PhaseDancer enables extension of the incomplete complex SD-rich subtelomeric regions of Great Ape chromosomes orthologous to the human chromosome 2 (HSA2) fusion site, informing a model of HSA2 formation and unravelling the evolution of human and Great Ape genomes.
The role of noise in denoising models for anomaly detection in medical images
Authors: Antanas Kascenas, Pedro Sanchez, Patrick Schrempf, Chaoyang Wang, William Clackett, Shadia S. Mikhael, Jeremy P. Voisey, Keith Goatman, Alexander Weir, Nicolas Pugeault, Sotirios A. Tsaftaris, Alison Q. O’Neil
Journal: Medical Image Analysis (2023)
Coupling of co-transcriptional splicing and 3’ end Pol II pausing during termination in Arabidopsis
Authors: Sixian Zhou, Fengli Zhao, Danling Zhu, Qiqi Zhang, Ziwei Dai, Zhe Wu
Journal: Genome biology (2023)

Abstract Background In Arabidopsis, RNA Polymerase II (Pol II) often pauses within a few hundred base pairs downstream of the polyadenylation site, reflecting efficient transcriptional termination, but how such pausing is regulated remains largely elusive. Result Here, we analyze Pol II dynamics at 3’ ends by combining comprehensive experiments with mathematical modelling. We generate high-resolution serine 2 phosphorylated (Ser2P) Pol II positioning data specifically enriched at 3’ ends and define a 3’ end pause index (3’PI). The position but not the extent of the 3’ end pause correlates with the termination window size. The 3’PI is not decreased but even mildly increased in the termination deficient mutant xrn3, indicating 3’ end pause is a regulatory step early during the termination and before XRN3-mediated RNA decay that releases Pol II. Unexpectedly, 3’PI is closely associated with gene exon numbers and co-transcriptional splicing efficiency. Multiple exons genes often display stronger 3’ end pauses and more efficient on-chromatin splicing than genes with fewer exons. Chemical inhibition of splicing strongly reduces the 3’PI and disrupts its correlation with exon numbers but does not globally impact 3’ end readthrough levels. These results are further confirmed by fitting Pol II positioning data with a mathematical model, which enables the estimation of parameters that define Pol II dynamics. Conclusion Our work highlights that the number of exons via co-transcriptional splicing is a major determinant of Pol II pausing levels at the 3’ end of genes in plants.
Subsequent female breast cancer risk associated with anthracycline chemotherapy for childhood cancer
Authors: Yuehan Wang, Cécile M. Ronckers, Flora E. van Leeuwen, Chaya S. Moskowitz, Wendy Leisenring, Gregory T. Armstrong, Florent de Vathaire, Melissa M. Hudson, Claudia E. Kuehni, Michael A. Arnold, Charlotte Demoor-Goldschmidt, Daniel M. Green, Tara O. Henderson, Rebecca M. Howell, Matthew J. Ehrhardt, Joseph P. Neglia, Kevin C. Oeffinger, Helena J. H. van der Pal, Leslie L. Robison, Michael Schaapveld, Lucie M. Turcotte, Nicolas Waespe, Leontien C. M. Kremer, Jop C. Teepen, Flora E. van Leeuwen, Florent de Vathaire, Helena J. H. van der Pal, Nadia Haddy, Ibrahima Diallo, K. Scott Baker, Amy Berrington de González, Miriam R. Conces, Louis S. Constine, Mike Hawkins, Jacqueline J. Loonen, Marloes Louwerens, Geert O. Janssens, Lene Mellemkjaer, Raoul Reulen, Jeanette F. Winther
Journal: Nature Medicine (2023)

Abstract Anthracycline-based chemotherapy is associated with increased subsequent breast cancer (SBC) risk in female childhood cancer survivors, but the current evidence is insufficient to support early breast cancer screening recommendations for survivors treated with anthracyclines. In this study, we pooled individual patient data of 17,903 survivors from six well-established studies, of whom 782 (4.4%) developed a SBC, and analyzed dose-dependent effects of individual anthracycline agents on developing SBC and interactions with chest radiotherapy. A dose-dependent increased SBC risk was seen for doxorubicin (hazard ratio (HR) per 100 mg m − 2 : 1.24, 95% confidence interval (CI): 1.18–1.31), with more than twofold increased risk for survivors treated with ≥200 mg m −2 cumulative doxorubicin dose versus no doxorubicin (HR: 2.50 for 200–299 mg m − 2 , HR: 2.33 for 300–399 mg m − 2 and HR: 2.78 for ≥400 mg m − 2 ). For daunorubicin, the associations were not statistically significant. Epirubicin was associated with increased SBC risk (yes/no, HR: 3.25, 95% CI: 1.59–6.63). For patients treated with or without chest irradiation, HRs per 100 mg m − 2 of doxorubicin were 1.11 (95% CI: 1.02–1.21) and 1.26 (95% CI: 1.17–1.36), respectively. Our findings support that early initiation of SBC surveillance may be reasonable for survivors who received ≥200 mg m − 2 cumulative doxorubicin dose and should be considered in SBC surveillance guidelines for survivors and future treatment protocols.
Suppression of cytokine release syndrome during CAR-T-cell therapy via a subcutaneously injected interleukin-6-adsorbing hydrogel
Authors: Xianlei Li, Ningqiang Gong, Falin Tian, Shangkun Zhang, Yuxuan Zhang, Yufei Wang, Guangchao Qing, Yongchao Wang, Fangzhou Li, Yihui Xu, Linlin Zhang, Jinjin Wang, Qiankun Ni, Yaling Gan, Chaojiang Gu, Huaidong Jiang, Xingxu Huang, Xinghua Shi, Tongcun Zhang, Yan Wu, Xing-Jie Liang
Journal: Nature Biomedical Engineering (2023)
Norepinephrine modulates calcium dynamics in cortical oligodendrocyte precursor cells promoting proliferation during arousal in mice
Authors: Tsai-Yi Lu, Priyanka Hanumaihgari, Eric T. Hsu, Amit Agarwal, Riki Kawaguchi, Peter A. Calabresi, Dwight E. Bergles
Journal: Nature Neuroscience (2023)
Mechanistic understanding of individual outcomes: Challenges and alternatives to genetic designs
Authors: Olesya Bondarenko
Journal: Behavioral and Brain Sciences (2023)

Abstract I argue that advancing “second-generation” or mechanistic causal knowledge of individual outcomes requires a comprehensive research programme that uses a variety of different methods in addition to the ones described in the paper under discussion. I also highlight that environment-focused approaches can be as instrumental in identifying potential phenotypic causes as gene-focused approaches.
Publisher Correction: Performance and effectiveness of hepatocellular carcinoma screening in individuals with HBsAg seropositivity in China: a multicenter prospective study
Authors: Hongmei Zeng, Maomao Cao, Changfa Xia, Dongmei Wang, Kun Chen, Zheng Zhu, Ruiying Fu, Shaokai Zhang, Jinyi Zhou, Huadong Wang, Xianyun Qi, Shuguang Dai, Yong Chen, Zhong Sun, Hao Ding, Qingwen Li, Hui Zhao, Xuehong Zhang, Jakub Morze, John S. Ji, Feng Sun, Xueqin Yu, Chunfeng Qu, Wanqing Chen
Journal: Nature Cancer (2023)
NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial
Authors: Zev A Wainberg, Davide Melisi, Teresa Macarulla, Roberto Pazo Cid, Sreenivasa R Chandana, Christelle De La Fouchardière, Andrew Dean, Igor Kiss, Woo Jin Lee, Thorsten O Goetze, Eric Van Cutsem, A Scott Paulson, Tanios Bekaii-Saab, Shubham Pant, Richard A Hubner, Zhimin Xiao, Huanyu Chen, Fawzi Benzaghou, Eileen M O'Reilly
Journal: The Lancet (2023)

Pancreatic ductal adenocarcinoma remains one of the most lethal malignancies, with few treatment options. NAPOLI 3 aimed to compare the efficacy and safety of NALIRIFOX versus nab-paclitaxel and gemcitabine as first-line therapy for metastatic pancreatic ductal adenocarcinoma (mPDAC).
Dynamic lipidome alterations associated with human health, disease and ageing
Authors: Daniel Hornburg, Si Wu, Mahdi Moqri, Xin Zhou, Kevin Contrepois, Nasim Bararpour, Gavin M. Traber, Baolong Su, Ahmed A. Metwally, Monica Avina, Wenyu Zhou, Jessalyn M. Ubellacker, Tejaswini Mishra, Sophia Miryam Schüssler-Fiorenza Rose, Paula B. Kavathas, Kevin J. Williams, Michael P. Snyder
Journal: Nature Metabolism (2023)

Abstract Lipids can be of endogenous or exogenous origin and affect diverse biological functions, including cell membrane maintenance, energy management and cellular signalling. Here, we report &gt;800 lipid species, many of which are associated with health-to-disease transitions in diabetes, ageing and inflammation, as well as cytokine–lipidome networks. We performed comprehensive longitudinal lipidomic profiling and analysed &gt;1,500 plasma samples from 112 participants followed for up to 9 years (average 3.2 years) to define the distinct physiological roles of complex lipid subclasses, including large and small triacylglycerols, ester- and ether-linked phosphatidylethanolamines, lysophosphatidylcholines, lysophosphatidylethanolamines, cholesterol esters and ceramides. Our findings reveal dynamic changes in the plasma lipidome during respiratory viral infection, insulin resistance and ageing, suggesting that lipids may have roles in immune homoeostasis and inflammation regulation. Individuals with insulin resistance exhibit disturbed immune homoeostasis, altered associations between lipids and clinical markers, and accelerated changes in specific lipid subclasses during ageing. Our dataset based on longitudinal deep lipidome profiling offers insights into personalized ageing, metabolic health and inflammation, potentially guiding future monitoring and intervention strategies.
Research progress on the role of extracellular vesicles in neurodegenerative diseases
Authors: Zhengzhe Li, Xiaoling Wang, Xiaoxing Wang, Xiaomei Yi, Yin Kwan Wong, Jiyang Wu, Fangfang Xie, Die Hu, Qi Wang, Jigang Wang, Tianyu Zhong
Journal: Translational Neurodegeneration (2023)

Abstract Neurodegenerative diseases, such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis, and Huntington’s disease, affect millions of people worldwide. Tremendous efforts have been put into disease-related research, but few breakthroughs have been made in diagnostic and therapeutic approaches. Extracellular vesicles (EVs) are heterogeneous cell-derived membrane structures that arise from the endosomal system or are directly separated from the plasma membrane. EVs contain many biomolecules, including proteins, nucleic acids, and lipids, which can be transferred between different cells, tissues, or organs, thereby regulating cross-organ communication between cells during normal and pathological processes. Recently, EVs have been shown to participate in various aspects of neurodegenerative diseases. Abnormal secretion and levels of EVs are closely related to the pathogenesis of neurodegenerative diseases and contribute to disease progression. Numerous studies have proposed EVs as therapeutic targets or biomarkers for neurodegenerative diseases. In this review, we summarize and discuss the advanced research progress on EVs in the pathological processes of several neurodegenerative diseases. Moreover, we outline the latest research on the roles of EVs in neurodegenerative diseases and their therapeutic potential for the diseases.
A designer peptide against the EAG2–Kvβ2 potassium channel targets the interaction of cancer cells and neurons to treat glioblastoma
Authors: Weifan Dong, Adam Fekete, Xiaodi Chen, Hongwei Liu, Greg L. Beilhartz, Xin Chen, Shahrzad Bahrampour, Yi Xiong, Qi Yang, Hongyu Zhao, Tian Kong, Malia S. Morioka, Geena Jung, Ji-Eun Kim, Daniel Schramek, Peter B. Dirks, Yuanquan Song, Tae-Hee Kim, Ye He, Siyi Wanggou, Xuejun Li, Roman A. Melnyk, Lu-Yang Wang, Xi Huang
Journal: Nature Cancer (2023)
Bimekizumab treatment in biologic DMARD-naïve patients with active psoriatic arthritis: 52-week efficacy and safety results from the phase III, randomised, placebo-controlled, active reference BE OPTIMAL study
Authors: Christopher T Ritchlin, Laura C Coates, Iain B McInnes, Philip J Mease, Joseph F Merola, Yoshiya Tanaka, Akihiko Asahina, Laure Gossec, Alice B Gottlieb, Richard B Warren, Barbara Ink, Rajan Bajracharya, Vishvesh Shende, Jason Coarse, Robert Bm Landewé
Journal: Annals of the Rheumatic Diseases (2023)

Bimekizumab (BKZ) is a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)-17F in addition to IL-17A. BKZ treatment has demonstrated superior efficacy versus placebo (PBO) at Week 16 in biologic disease-modifying antirheumatic drug (DMARD)-naïve patients with active psoriatic arthritis (PsA). Here, we report long-term efficacy and safety to Week 52.BE OPTIMAL comprised a 16-week, double-blind, PBO-controlled period, then 36 weeks treatment-blind. Patients were randomised 3:2:1 to subcutaneous BKZ 160 mg every 4 weeks, PBO with switch to BKZ at Week 16, or reference arm (adalimumab (ADA) 40 mg every 2 weeks). Efficacy outcomes included the American College of Rheumatology (ACR) response criteria 20/50/70, Psoriasis Area and Severity Index (PASI) 75/90/100 in patients with baseline psoriasis affecting ≥3% body surface area and minimal disease activity (MDA); non-responder imputation.ACR20/50/70, PASI75/90/100 and MDA responses were sustained with BKZ to Week 52, consistent with results observed at Week 16. Patients who switched to BKZ at Week 16 demonstrated improvements in efficacy with similar results to BKZ-randomised patients by Week 52.To Week 52, 555/702 (79.1%) patients had ≥1 treatment-emergent adverse event (TEAE) during BKZ treatment; 113/140 (80.7%) on ADA. On BKZ, 46 (6.6%) patients had serious TEAEs. 54 (7.7%) Candida infections occurred during BKZ treatment and 1 (0.7%) during ADA; all cases were localised and non-serious. One death occurred in a BKZ-treated patient, unrelated to treatment.The efficacy of BKZ in bDMARD-naïve patients with PsA was sustained from Week 16 to Week 52. BKZ was well tolerated with no new safety signals observed.NCT03895203.
Atopic and non-atopic effects of fish oil supplementation during pregnancy
Authors: Hans Bisgaard, Marianne Mikkelsen, Morten Arendt Rasmussen, Astrid Sevelsted, Ann-Marie Malby Schoos, Nicklas Brustad, Anders U Eliasen, Jonathan Thorsen, Bo Chawes, Gözde Gürdeniz, Andreanne Morin, Ken Stark, Jakob Stokholm, Carole Ober, Casper Emil Tingskov Pedersen, Klaus Bønnelykke
Journal: Thorax (2023)

Background We recently conducted a double-blinded randomised controlled trial showing that fish-oil supplementation during pregnancy reduced the risk of persistent wheeze or asthma in the child by 30%. Here, we explore the mechanisms of the intervention. Methods 736 pregnant women were given either placebo or n-3 long-chain polyunsaturated fatty acids (LCPUFAs) in the third trimester in a randomised controlled trial. Deep clinical follow-up of the 695 children in the trial was done at 12 visits until age 6 years, including assessment of genotype at the fatty acid desaturase (FADS) locus, plasma fatty acids, airway DNA methylation, gene expression, microbiome and metabolomics. Results Supplementation with n-3 LCPUFA reduced the overall risk of non-atopic asthma by 73% at age 6 (relative risk (RR) 0.27 (95% CI 0.06 to 0.85), p=0.042). In contrast, there was no overall effect on asthma with atopic traits (RR 1.42 (95% CI 0.63 to 3.38), p=0.40), but this was significantly modified by maternal FADS genotype and LCPUFA blood levels (interaction p&lt;0.05), and supplementation did reduce the risk of atopic asthma in the subgroup of mothers with FADS risk variants and/or low blood levels of n-3 LCPUFA before the intervention (RR 0.31 (95% CI 0.11 to 0.75), p=0.016). Furthermore, n-3 LCPUFA significantly reduced the number of infections (croup, gastroenteritis, tonsillitis, otitis media and pneumonia) by 16% (incidence rate ratio 0.84 (95% CI 0.74 to 0.96), p=0.009). Conclusions n-3 LCPUFA supplementation in pregnancy showed protective effects on non-atopic asthma and infections. Protective effects on atopic asthma depended on maternal FADS genotype and n-3 LCPUFA levels. This indicates that the fatty acid pathway is involved in multiple mechanisms affecting the risk of asthma subtypes and infections. Trial registration number NCT00798226 .
Comprehensive Management of ANOCA, Part 2—Program Development, Treatment, and Research Initiatives
Authors: Nathaniel R. Smilowitz, Megha Prasad, R. Jay Widmer, Olga Toleva, Odayme Quesada, Nadia R. Sutton, Amir Lerman, Harmony R. Reynolds, Manoj Kesarwani, Michael P. Savage, Joseph M. Sweeny, Katherine B. Janaszek, Ailin Barseghian El-Farra, Noa Holoshitz, Ki Park, Ahmed Albadri, John A. Blair, Allen Jeremias, Kathleen E. Kearney, Yuhei Kobayashi, Steven E.S. Miner, Bruce A. Samuels, Samit M. Shah, Viviany R. Taqueti, Janet Wei, William F. Fearon, Jeffery W. Moses, Timothy D. Henry, Jennifer A. Tremmel
Journal: Journal of the American College of Cardiology (2023)
Transcriptional and epigenetic decoding of the microglial aging process
Authors: Xiaoyu Li, Yuxin Li, Yuxiao Jin, Yuheng Zhang, Jingchuan Wu, Zhen Xu, Yubin Huang, Lin Cai, Shuai Gao, Taohui Liu, Fanzhuo Zeng, Yafei Wang, Wenxu Wang, Ti-Fei Yuan, Hengli Tian, Yousheng Shu, Feifan Guo, Wei Lu, Ying Mao, Xifan Mei, Yanxia Rao, Bo Peng
Journal: Nature Aging (2023)

Abstract As important immune cells, microglia undergo a series of alterations during aging that increase the susceptibility to brain dysfunctions. However, the longitudinal characteristics of microglia remain poorly understood. In this study, we mapped the transcriptional and epigenetic profiles of microglia from 3- to 24-month-old mice. We first discovered unexpected sex differences and identified age-dependent microglia (ADEM) genes during the aging process. We then compared the features of aging and reactivity in female microglia at single-cell resolution and epigenetic level. To dissect functions of aged microglia excluding the influence from other aged brain cells, we established an accelerated microglial turnover model without directly affecting other brain cells. By this model, we achieved aged-like microglia in non-aged brains and confirmed that aged-like microglia per se contribute to cognitive decline. Collectively, our work provides a comprehensive resource for decoding the aging process of microglia, shedding light on how microglia maintain brain functions.
Prediction during language comprehension: what is next?
Authors: Rachel Ryskin, Mante S. Nieuwland
Journal: Trends in Cognitive Sciences (2023)

Prediction is often regarded as an integral aspect of incremental language comprehension, but little is known about the cognitive architectures and mechanisms that support it. We review studies showing that listeners and readers use all manner of contextual information to generate multifaceted predictions about upcoming input. The nature of these predictions may vary between individuals owing to differences in language experience, among other factors. We then turn to unresolved questions which may guide the search for the underlying mechanisms. (i) Is prediction essential to language processing or an optional strategy? (ii) Are predictions generated from within the language system or by domain-general processes? (iii) What is the relationship between prediction and memory? (iv) Does prediction in comprehension require simulation via the production system? We discuss promising directions for making progress in answering these questions and for developing a mechanistic understanding of prediction in language.
Anti-GM-CSF otilimab versus sarilumab or placebo in patients with rheumatoid arthritis and inadequate response to targeted therapies: a phase III randomised trial (contRAst 3)
Authors: Peter C Taylor, Michael E Weinblatt, Iain B McInnes, Tatsuya Atsumi, Vibeke Strand, Tsutomu Takeuchi, Marguerite Bracher, David Brooks, John Davies, Christopher Goode, Anubha Gupta, Sumanta Mukherjee, Ciara O’Shea, Didier Saurigny, Lorrie A Schifano, Celia Shelton, Julia E Smith, Millie Wang, Reena Wang, Sarah Watts, Roy M Fleischmann
Journal: Annals of the Rheumatic Diseases (2023)

To investigate the efficacy and safety of otilimab, an anti-granulocyte-macrophage colony-stimulating factor antibody, in patients with active rheumatoid arthritis and an inadequate response to conventional synthetic (cs) and biologic disease-modifying antirheumatic drugs (DMARDs) and/or Janus kinase inhibitors.
Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial
Authors: Peter M Voorhees, Douglas W Sborov, Jacob Laubach, Jonathan L Kaufman, Brandi Reeves, Cesar Rodriguez, Ajai Chari, Rebecca Silbermann, Luciano J Costa, Larry D Anderson, Nitya Nathwani, Nina Shah, Naresh Bumma, Yvonne A Efebera, Sarah A Holstein, Caitlin Costello, Andrzej Jakubowiak, Tanya M Wildes, Robert Z Orlowski, Kenneth H Shain, Andrew J Cowan, Shira Dinner, Huiling Pei, Annelore Cortoos, Sharmila Patel, Thomas S Lin, Saad Z Usmani, Paul G Richardson
Journal: The Lancet Haematology (2023)
Antiviral efficacy of the SARS-CoV-2 XBB breakthrough infection sera against omicron subvariants including EG.5
Authors: Yu Kaku, Yusuke Kosugi, Keiya Uriu, Jumpei Ito, Alfredo A Hinay, Jin Kuramochi, Kenji Sadamasu, Kazuhisa Yoshimura, Hiroyuki Asakura, Mami Nagashima, Kei Sato
Journal: The Lancet Infectious Diseases (2023)
Approaches of laparoscopic anatomical liver resection of segment 8 for hepatocellular carcinoma: a retrospective cohort study of short-term results at multiple centers in China
Authors: Xingru Wang, Jianwei Li, Jun Cao, Qifan Zhang, Yonggang Wei, Wei Cheng, Xiao Liang, Feng Tian, Xin Wang, Hongwei Xu, Jie Chen, Ning Zhou, Zaibo Yang, Changcheng Tao, Hongguang Wang
Journal: International Journal of Surgery (2023)

Background: Laparoscopic anatomical liver resection of segment 8 (LALR-S8) remains a challenge for anatomical laparoscopic segmentectomy. Most current reports on LALR-S8 are case series using one surgical approach, and there is a lack of multicenter data on identifying intersegmental planes using different approaches. In this study, we aimed to elucidate the short-term results of three different approaches for LALR-S8 for hepatocellular carcinoma (HCC), focusing on intersegmental plane determination, and to reflect on current practice regarding different approaches at multiple centers in China. Materials and methods: The clinical cohort data of 122 patients who underwent LALR-S8 for HCC at seven leading centers in China were retrospectively analyzed. The surgical procedures of all approaches were summarized and standardized according to the method of the Glissonean pedicle of segment 8 identification. The postoperative short-term outcomes and oncological results of the three approaches were evaluated and compared. Results: Three approaches were used: laparoscopic ultrasonography-guided indocyanine green (ICG) fluorescent positive staining approach (11/122, 9.02%), hepatic vein-guided approach (99/122, 81.15%), and Glissonean ICG fluorescent negative staining approach (12/122, 9.83%). Seven (5.73%) patients experienced complications according to the Clavien–Dindo (CD) classification, and the rate of grade ≥IIIa complications was 2.46%. The R0 resection rates among the groups (margin &gt;1 mm) and the margin width showed no statistical difference. Conclusion: LALR-S8 is safe and feasible for treating HCC under standardized surgical techniques and appropriate surgical approaches. The three reported approaches had comparable short-term oncological outcomes, while the hepatic vein-guided approach was most commonly used.
Variant allele frequency: a decision-making tool in precision oncology?
Authors: Luca Boscolo Bielo, Dario Trapani, Matteo Repetto, Edoardo Crimini, Carmine Valenza, Carmen Belli, Carmen Criscitiello, Antonio Marra, Vivek Subbiah, Giuseppe Curigliano
Journal: Trends in cancer (2023)